View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 23, 2020

Cereno Scientific looks to enter PAH market with its leading product CS-1

By Victoria Smith

In March, the US Food and Drug Administration (FDA) granted Cereno Scientific’s preclinical candidate CS-1 (valproic acid) Orphan Drug Designation for pulmonary arterial hypertension.

GlobalData supposes that CS-1 could fill a gap in the market due to its innovative mechanism of action, particularly epigenetic modulation of cardiovascular disease by histone deacetylase inhibition.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy